Eli Lilly says an experimental drug slows Alzheimer's worsening

2024-12-25 12:31:58 source:lotradecoin comparison category:Stocks

WASHINGTON — Eli Lilly and Co. said Wednesday its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced in a press release.

The drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer's.

A similar amyloid-targeting drug, Eisai and Biogen's Leqembi, recently hit the market with similar evidence that it could modestly slow Alzheimer's — and also some safety concerns, brain swelling or small brain bleeds.

Donanemab also comes with that risk. Lilly said in its study, the brain side effects caused the deaths of two participants and a third also died after a serious case.

The preliminary study results haven't been vetted by outside experts. Indianapolis-based Lilly plans to release more details at an international Alzheimer's meeting this summer and is seeking Food and Drug Administration approval of the drug.

More:Stocks

Recommend

Taylor Swift makes history as most decorated artist at Billboard Music Awards

Taylor Swift celebrated the eve of her 35th birthday by making history at the Billboard Music Awards

Ahead of James Patterson's new book release, the author spills on his writing essentials

In a weekly series, USA TODAY’s The Essentials, celebrities share what fuels their lives.James Patte

What can ordinary taxpayers learn from the $700m Shohei Ohtani baseball megadeal?

Rich people have more money to spend on everything, including tax advice.So ordinary taxpayers shoul